Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 14 November 2017
Vedrop is indicated in vitamin E deficiency due to digestive malabsorption in paediatric patients with congenital chronic cholestasis or hereditary chronic cholestasis, from birth (full term newborns) up to 18 years of age.
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
The aim of this study is to evaluate bone microarchitecture of paediatric CF patients matched to sex-age-pubertal status-healthy volonteers. In...
Added 5 years ago
A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long-Term Ivacaftor Treatment in Subjects 6 Years of Age and Older with Cystic Fibrosis and a Non-G551D CFTR Mutation
To evaluate the safety of long-term ivacaftor treatment in subjects with cystic fibrosis (CF)
Added 6 years ago
A Phase 3, 2 Part, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Pharmacokinetics, Efficacy and Safety of VX 770 in Subjects Aged 6 to 11 Years with Cystic Fibrosis and the G551D Mutation
Part A: To evaluate the pharmacokinetics of a single dose of orally administered VX 770 treatment in subjects 6 to...
Added 9 years ago
The purpose of the study is to determine the effect of setmelanotide (RM-493) on weight and other factors in patients with pro-opiomelanocortin (POMC) deficiency obesity due to rare bi-allelic loss-of function POMC or PCSK1 genetic mutations.
Added 1 year ago
To investigate the potential antiepileptic effects of cannabidiol (GWP42003-P) in children and young adults with Dravet syndrome.
Added 3 years ago
Eluxadoline (Truberzi) is an orally administered, minimally absorbed agent that acts locally in the gastrointestinal tract as a mixed µ-opioid receptor agonist and δ-opioid receptor antagonist.
Added 7 months ago
Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease.
Introduction: Iron deficiency anemia affects up to three quarters of patients with inflammatory bowel disease (IBD). It can significantly impact...
Added 2 years ago
Advances in the management of constipation-predominant irritable bowel syndrome: the role of linaclotide.
Constipation-predominant irritable bowel syndrome (IBS-C) is a commonly prevalent and clinically challenging disorder to treat. Until recently, most therapeutic agents...
Added 3 years ago
Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer
The number of patients with chronic gastrointestinal (GI) symptoms after cancer therapies which have a moderate or severe impact on...
Added 6 years ago
The association between celiac disease (CD) and liver disease in pediatrics is widely recognized, but its prevalence is unknown. This...
Added 4 years ago
This guideline applies to children younger than 5 years who present to a healthcare professional for advice in any setting....
Added 8 years ago
|Agency product number||EMEA/H/C/000920|
|Date First Approved||24-07-2009|
|Type||Medicinal product subject to restricted medical prescription|
|Marketing authorisation holder||Orphan Europe S.A.R.L.|
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reacti